POLR3G and plasma cell myeloma: Notably, POLR3G upregulation has been linked with poor survival outcomes across a variety of cancers, including in patients with lung adenocarcinoma (Sun et al., 2022), hepatocellular carcinoma (Dai et al., 2021), transitional cell carcinoma (Liu et al., 2020), multiple myeloma (Yang et al., 2021), and other forms of cancer (Van Bortle et al., 2022).